Osteopontin Levels in Patients With Chronic Kidney Disease Stage 5 on Hemodialysis Directly Correlate With Intact Parathyroid Hormone and Alkaline Phosphatase

被引：8

作者：

Druck, Aleksander ^{[1
,2
]}

Patel, Dimpi ^{[1
]}

Bansal, Vinod ^{[3
]}

Hoppensteadt, Debra ^{[2
]}

Fareed, Jawed ^{[2
]}

机构：

[1] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA

[2] Ctr Translat Res & Educ, Hemostasis & Thrombosis Labs, 2160 S 1st Ave, Maywood, IL 60153 USA

[3] Loyola Univ Med Ctr, Dept Med, Maywood, IL 60153 USA

来源：

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | 2019年 / 25卷

基金：

美国国家卫生研究院;

关键词：

kidney disease; hemodialysis; biomarkers; mineral and bone disorder; osteopontin; BONE-MINERAL DENSITY; VITAMIN-D-RECEPTOR; VASCULAR CALCIFICATION; HIP FRACTURE; ASSOCIATION; BIOMARKERS; MARKERS; RISK; MORTALITY; DISORDER;

D O I：

10.1177/1076029619896621

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Chronic kidney disease stage 5 (CKD5) marks the fifth stage of renal failure, frequently causing dysregulation of bone and mineral metabolism. Challenges exist in evaluating and managing chronic kidney disease-mineral bone disorder (CKD-MBD) with the standard panel of biomarkers. Our objective was to profile osteopontin (OPN) in patients with CKD5 on maintenance hemodialysis (CKD5-HD) and elucidate its relationship to phosphorus (P), calcium (Ca2+), alkaline phosphatase (AP), and intact parathyroid hormone (iPTH) to improve understanding of the present model of CKD-MBD. Elevation of plasma OPN was seen in the CKD5-HD cohort (n = 92; median: 240.25 ng/mL, interquartile range [IQR]: 169.85 ng/mL) compared to a normal group (n = 49; median: 63.30 ng/mL, IQR: 19.20 ng/mL; p < .0001). Spearman correlation tests revealed significant positive correlations of OPN with iPTH (p < .0001; r = 0.561, 95% confidence interval = 0.397-0.690) and OPN with AP (p < .0001; r = 0.444, 95% confidence interval = 0.245-0.590) in CKD5-HD patients. Ultimately, OPN may play an integral role in the MBD axis, suggesting that it may be important to actively monitor OPN when managing CKD5-HD.

引用

页数：5

共 39 条

[1] Plasma Osteopontin Levels and Adverse Cardiovascular Outcomes in the PEACE Trial [J].